Latest market price
229.74
+15.30+7.13%
OverviewShort InterestFilings
JAZZQT81Jazz Pharmaceuticals plc·NASDAQ
229.74+7.13%
Earnings
Up 7.1% — Q3 2026 EPS beat expectations by 4%, driving positive investor sentiment.
High confidence
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
HALO-0.26%$128.62BBIO-1.29%$74.03NBIX+13.42%$164.85ASND+0.48%$250.17SMMT+6.76%$15.80TECH-0.01%$72.66BMRN-3.10%$55.66EXEL+3.11%$72.31
Snapshot
Index—P/E14.66EPS (ttm)14.63Insider Own3.94%Shs Outstand64.91MPerf Week11.10%
Market Cap13.92BForward P/E8.26EPS next Y25.97Insider Trans-4.74%Shs Float62.36MPerf Month-2.67%
Enterprise Value16.12BPEG0.58EPS next Q—Short Float9.40%Perf Quarter-12.17%
Income940.00MP/S3.03EPS this Y71.00%Short Ratio6.61Perf Half Y8.24%
Sales4.60BP/B2.90EPS next Y84.54%ROA8.49%Short Interest5.86MPerf YTD35.14%
Book/sh73.97P/C6.33EPS next 5Y25.28%ROE21.37%52W High266.38 -13.75%Perf Year66.91%
Cash/sh33.89P/FCF9.02EPS past 3/5Y—ROIC14.46%52W Low128.80 78.37%Perf 3Y82.23%
Dividend Est.—EV/EBITDA9.83Sales past 3/5Y5.27% 12.54%Gross Margin84.67%Volatility3.62% 3.34%Perf 5Y67.24%
Dividend TTM—EV/Sales3.50EPS Y/Y TTM—Oper. Margin31.05%ATR (14)7.43Perf 10Y93.20%
Dividend Ex-Date—Quick Ratio1.58Sales Y/Y TTM12.58%Profit Margin20.45%RSI (14)59.42Recom2.10
Dividend Gr. 3/5Y—Current Ratio1.78EPS Q/Q-147.72%SMA207.31%Beta0.37Target Price292.27
Payout0.00%Debt/Eq0.92Sales Q/Q15.49%SMA50-0.40%Rel Volume1.88Prev Close214.44
Employees2,890LT Debt/Eq0.70EarningsFeb 23SMA2005.80%Avg Volume892.00KPrice229.74
IPO DateJun 01, 2007Option/ShortYes / YesEPS/Sales Surpr.4.20% —Net Debt/EBITDA1.34Volume1,680,855Change7.13%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-21-26ReiteratedMorgan StanleyOverweight$322 → $314
Oct-08-26ReiteratedRBC CapitalOutperform$299 → $296
Oct-07-26ReiteratedTruist SecuritiesBuy$281 → $286
Sep-24-26ResumedGoldman SachsBuy$169 → $337
Sep-11-26ReiteratedUBSBuy$315 → $337
Sep-10-26ReiteratedBarclaysOverweight$270 → $271
Aug-28-26ReiteratedRBC CapitalOutperform$277 → $299
Aug-26-26ReiteratedRBC CapitalOutperform$194 → $277
Aug-26-26ReiteratedCanaccord GenuityBuy$290 → $300
Aug-26-26ReiteratedDeutsche BankBuy$287 → $300
Latest News· Times ET
Today
Today04:15PM
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferencesprnewswire.com
12:16PM
JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales Viewzacks.com
11:36AM
4 Biotech Stocks Seeing Unusual Options Volume Todayschaeffersresearch.com
Nov-02-26
Nov-02-2609:58PM
Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcriptseekingalpha.com
08:14PM
Jazz Pharmaceuticals Q3 Earnings Call Highlightsmarketbeat.com
07:31PM
Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimateszacks.com
06:25PM
Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimateszacks.com
04:05PM
Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Resultsprnewswire.com
08:30AM
Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026prnewswire.com
Oct-28-26
Oct-28-2611:12AM
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300Benzinga
Oct-27-26
Oct-27-2604:09PM
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Enginefool.com
Oct-26-26
Oct-26-2611:01AM
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out forzacks.com
Oct-23-26
Oct-23-2610:15AM
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026prnewswire.com
Oct-21-26
Oct-21-2610:00AM
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?Yahoo
Oct-20-26
Oct-20-2603:31AM
Jazz Pharmaceuticals PLC $JAZZ Position Lifted by CWA Asset Management Group LLCdefenseworld.net
Company

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue4,6014,2684,0693,834—————
Cost of Goods Sold Incl. D&A705503446436—————
Gross Profit3,8963,7643,6233,399—————
Selling, General and Administrative Excl. Other1,6791,8091,3851,343—————
Research and Development754783884850—————
Other Operating Expense35948638627—————
Operating Income1,429224717579—————
Interest Expense194195238289—————
Unusual Expense
—————————
Non-Operating Income (Expense)-507-658-106—————
Net Income Before Taxes727-629469295—————
Income Taxes-213-272-91-120—————
Consolidated Net Income940-356560415—————
Net Income From Continuing Operations940-356560415—————
Net Income940-356560415—————
EPS (Recurring)15.20-5.849.066.55—————
EPS (Basic, Before Extraordinaries)15.20-5.849.066.55—————
EPS (Diluted)14.63-5.848.656.10—————
EBITDA1,6402631,5221,449—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio15.70—14.2420.16—————
Price To Sales Ratio3.152.431.882.02—————
Gross Margin84.6888.1989.0488.65—————
Operating Margin31.065.2517.6215.10—————
Net Margin20.43-8.3413.7610.82—————
Shares Outstanding63616263—————
Market Capitalization14,47410,3707,6357,749—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$282.20$237.61$193.03$148.44$103.85● Close Price0.00M5.20M10.41M15.61M20.81MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
GALA RENEE DPresident & CEOOct 06 '26Sale236.402,000472,800141,394Oct 07
COZADD BRUCE CDirectorOct 01 '26Sale230.336,0001,381,980345,875Oct 05
Patil Neena MEVP & Chief Legal OfficerSep 10 '26Sale240.941,200289,12847,671Sep 14
GALA RENEE DPresident & CEOSep 08 '26Sale243.032,000486,060143,394Sep 10
COZADD BRUCE CDirectorSep 01 '26Sale250.136,0001,500,780351,875Sep 02
Iannone RobertEVP, Global Head of R&D & CMOAug 27 '26Option Exercise125.8457,5007,235,860142,607Aug 31
Iannone RobertEVP, Global Head of R&D & CMOAug 27 '26Sale249.7076,92119,207,09765,686Aug 31
COZADD BRUCE CDirectorAug 03 '26Sale252.986,0001,517,880360,682Aug 05
COZADD BRUCE CDirectorJul 01 '26Sale240.476,0001,442,820366,682Jul 06
Smith Mark DouglasDirectorJun 15 '26Sale230.551,157266,7469,680Jun 17
Patil Neena MEVP & Chief Legal OfficerJun 10 '26Sale231.831,200278,19651,549Jun 12
Mulligan SeamusDirectorMay 28 '26Option Exercise138.083,415471,5431,183,028Jun 01
Pearce SamanthaEVP, Chief Commercial OfficerMay 28 '26Sale235.416,9071,625,97750,272Jun 01
Patil Neena MEVP & Chief Legal OfficerMay 28 '26Sale236.971,192282,46852,626Jun 01
Pearce SamanthaEVP, Chief Commercial OfficerMay 28 '26Option Exercise109.456,907755,97157,179Jun 01
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.